Unapproved Weight-Loss Peptide Causes Severe Oesophageal Tear in Patient

An Australian patient who consumed an unapproved peptide labeled as the weight-loss drug retatrutide was hospitalized with a life-threatening torn oesophagus, according to the Therapeutic Goods Administration (TGA). Laboratory testing conducted by the medicines regulator revealed that the product contained zero retatrutide and instead contained an undeclared, extremely high concentration of semaglutide, the active ingredient found in Ozempic and Wegovy.

The TGA's safety analysis determined that the amount of semaglutide present in the product was roughly eight times higher than the doses approved in standard TGA-assessed treatments. The excessive dosage triggered severe, uncontrollable vomiting in the patient, resulting in a rupture of the oesophagus.

Medical Risks of Counterfeit Peptides

Melbourne gastroenterologist Dr. Darcy Holt explained that an oesophageal tear is a medical emergency that can allow stomach contents to leak into the chest cavity near the heart and major blood vessels, causing severe infection. Dr. Holt noted that high doses of such drugs lead to extreme nausea and forceful vomiting, which can cause these severe tears. He added that unapproved peptides have also caused liver toxicity and severe secretory diarrhoea in patients.

The regulator noted that retatrutide is currently undergoing human clinical trials and has not received approval from the TGA or any equivalent international health authority. The TGA advised that the drug should never be used outside of official clinical trial environments.

Rising Use and Regulatory Warnings

TGA Chief Medical Advisor Dr. Robyn Langham warned that unapproved injectable peptides present severe hazards, including unknown substances, unpredictable dosages, lack of sterility, and potential contaminants that can trigger life-threatening infections or anaphylaxis.

The incident follows joint testing by the ABC and the University of Queensland, which previously detected black-market retatrutide vials containing doses significantly higher than stated on their labels. Dr. Holt reported a noticeable surge in patients disclosing the use of unapproved retatrutide over the past three to six months.